pegylated filgrastim + filgrastim

This entry refers to the comparative use of pegylated filgrastim and filgrastim as investigated by the Chinese Academy of Medical Sciences in a Phase 3 crossover trial for the prevention of chemotherapy-induced neutropenia. Pegylated filgrastim (PEG-rhG-CSF), specifically the version developed by GeneLeuk Biopharmaceutical (Jinyouli), is a long-acting recombinant human granulocyte colony-stimulating factor created by covalently attaching a 20 kDa polyethylene glycol molecule to the N-terminal residue of filgrastim. This modification significantly reduces renal clearance and extends the plasma half-life, allowing for a single subcutaneous injection per chemotherapy cycle. Filgrastim (rhG-CSF) is the standard, short-acting version that requires daily administration. Both agents act as agonists at the granulocyte colony-stimulating factor receptor (G-CSFR), stimulating the survival, proliferation, and differentiation of neutrophil precursors in the bone marrow. The Phase 3 study demonstrated that a single 100 μg/kg dose of pegylated filgrastim provides comparable efficacy and safety to daily 5 μg/kg doses of filgrastim in cancer patients receiving myelosuppressive chemotherapy.

Brand names

Jinyouli

Other names

pegfilgrastimfilgrastimpegylated recombinant human granulocyte colony-stimulating factor